Orchard Therapeutics Price to Book Ratio 2017-2021 | ORTX

Historical price to book ratio values for Orchard Therapeutics (ORTX) over the last 10 years. The current price to book ratio for Orchard Therapeutics as of October 22, 2021 is 0.88.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Orchard Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 1.89 0.86
2021-06-30 4.39 $2.19 2.00
2021-03-31 7.26 $2.39 3.04
2020-12-31 4.32 $1.82 2.38
2020-09-30 4.11 $2.12 1.94
2020-06-30 6.00 $2.33 2.58
2020-03-31 7.53 $2.72 2.77
2019-12-31 13.75 $3.09 4.45
2019-09-30 11.88 $3.52 3.38
2019-06-30 13.99 $3.86 3.63
2019-03-31 17.88 $3.35 5.34
2018-12-31 15.73 $3.63 4.34
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.237B $0.003B
Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76